Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry

Background Elexacaftor/tezacaftor/ivacaftor (ETI) has improved outcomes for people with cystic fibrosis (pwCF). This study evaluated changes in airway microbiological infection status after initiating ETI. Methods Using the European Cystic Fibrosis Society registry, pwCF who started ETI between 2019...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Mordechai Pollak, Simone Gambazza, Annalisa Orenti, Virginia De Rose, Dario Prais, Eitan Kerem, Meir Mei Zahav
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	European Respiratory Society 2025-08-01
Serie:	ERJ Open Research
Accesso online:	http://openres.ersjournals.com/content/11/4/01248-2024.full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!